Table 2.
Prevalence of complications at different time periods for the entire cohort (n = 204 patients)
| complications | M0-M3 n (%) |
M3-M6 n (%) |
M6-M9 n (%) |
M9-M12 n (%) |
M12-M18 n (%) |
M18-M24 n (%) |
|---|---|---|---|---|---|---|
| Infections | 51 (25.1) | 76 (37.6) | 77 (38.3) | 71 (35.5) | 50 (25.0) | 52 (26.1) |
| Arthralgia | 78 (38.2) | 80 (39.4) | 66 (32.8) | 70 (35.0) | 53 (26.5) | 49 (24.6) |
| Peripheral neuropathy | 50 (24.5) | 40 (19.7) | 36 (17.9) | 32 (16.0) | 22 (11.0) | 16 (8.0) |
| Gastritis | 20 (9.8) | 22 (10.8) | 21 (10.4) | 14 (7.0) | 9 (4.5) | 9 (4.5) |
| Erectile dysfunction | 26 (12.7) | 26 (12.8) | 29 (14.4) | 23 (11.5) | 23 (11.5) | 23 (11.5) |
| Libido disturbances | 26 (12.7) | 18 (8.9) | 20 (10.0) | 15 (7.5) | 16 (8.0) | 20 (10.0) |
| Osteoporosis | 8 (3.9) | 9 (4.4) | 8 (4.0) | 11 (5.5) | 15 (7.5) | 11 (5.5) |
| Hypogammaglobulinemia | 50 (24.4) | ND | ND | 68 (33.1) | ND | 49 (23.9) |
| Cardio-vascular events | 14 (6.8) | 9 (4.4) | 11 (5.3) | 17 (8.2) | 16 (7.8) | 11 (5.5) |
| Thyroid (benign) | 3 (1.4) | 3 (1.4) | 3 (1.4) | 4 (1.9) | 3 (1.4) | 3 (1.4) |
| Urogenitala | 14 (6.8) | 12 (5.8) | 15 (7.5) | 11 (5.5) | 15 (7.5) | 19 (9.2) |
| Ear, nose and throata | 15 (7.5) | 8 (3.9) | 15 (7.5) | 15 (7.5) | 8 (3.9) | 9 (4.5) |
| Pulmonarya | 19 (9.2) | 14 (7.0) | 11 (5.3) | 17 (8.2) | 9 (4.5) | 16 (7.8) |
| Second cancers | 3 (1.4) | 4 (1.9) | 2 (0.9) | 3 (1.4) | 5 (2.4) | 6 (2.9) |
a cancers and infections were excluded